Warfarin: An old drug but still interesting

Pharmacotherapy

Volumn 28, Issue 9, 2008, Pages 1081-1083

  Johnson, Julie A ^a,b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Bleeding; INR; Oral anticoagulant; Pharmacogenetics; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN;

ANTICOAGULATION; BLEEDING; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; EDITORIAL; GENETIC CODE; GENETIC VARIABILITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; THROMBOEMBOLISM; THROMBOGENESIS; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTICOAGULANTS; BLOOD COAGULATION DISORDERS; HEMORRHAGE; HUMANS; PHARMACOGENETICS; WARFARIN;

EID: 51849158285     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.9.1081     Document Type: Editorial

References (4)

1. Seto AC, Kenyon K, Wittkowsky AK. Discrepancies in identification of major bleeding events in patients taking warfarin. Pharmacotherapy 2008;28:1098-1103.
2. Limdi NA, Veenstra DL. Warfarin pharmacogenetics. Pharmacotherapy 2008;28:1084-97.
3. U.S. Food and Drug Administration. Warfarin product labeling. Available from http://www.fda.gov/cder/foi/label/2007/009218s105lblv2.pdf. Accessed July 1, 2008.
4. Gage B, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin [published online ahead of print February 27, 2008). Clin Pharmacol Ther. doi:10.1038/clpt.2008. 10.